✦ LIBER ✦

Clinical results of two different dose regimens with high-dose interferon-alpha and interleukin-2 in advanced renal cell cancer and malignant melanoma

✍ Scribed by K. Fenchel; A. Winkler; PS. Mitrou; D. Hoelzer; L. Bergmann

Book ID: 116167801
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 112 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)99912-j

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low dose cyclophosphamide, alpha-interfe

Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma

✍ J.P WersÄll; G. Masucci; A-L Hjelm; P. Ragnhammar; J. Fagerberg; J-E. FrÖdin; K. 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 657 KB

Dose efficacy study of two schedules of

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma

✍ Kruit, WHJ; Punt, CJA; Goey, SH; de Mulder, PHM; Gratama, JW; Eggermont, AMM; Bo 📂 Article 📅 1996 🏛 Nature Publishing Group 🌐 English ⚖ 763 KB

Long-term treatment with low doses of in

Long-term treatment with low doses of interleukin-2 and interferon-α: immunological effects in advanced renal cell cancer

✍ Laura Pavone; Simeone Andrulli; Rosaria Santi; Maria Majori; Carlo Buzio 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 184 KB

A phase I study of recombinant human int

A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma

✍ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN

Initial Clinical Response Predicts Outco

Initial Clinical Response Predicts Outcome and Is Associated With Dose Schedule in Metastatic Melanoma and Renal Cell Carcinoma Patients Treated With High-Dose Interleukin 2

✍ Kathryn Spanknebel; Kenneth Y. Cheung; John Stoutenburg; Karl Hurst-Wicker; Char 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 133 KB

Initial clinical response predicts outco

Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin-2

✍ K. Spanknebel; K. Hurst-Wicker; Y. K. Cheung; C. Hesdorffer; G. DeRaffele; H. Ka 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 148 KB